S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Altamira Therapeutics Short Interest Ratio and Short Volume

0.00 (0.00%)
(As of 12/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
136,321 shs
Average Volume
2.90 million shs
Market Capitalization
$17.13 million
P/E Ratio
Dividend Yield

Altamira Therapeutics (NASDAQ:CYTO) Short Interest Data

Current Short Volume
Previous Short Volume
Change Vs. Previous Month
Dollar Volume Sold Short
$182.16 thousand
Short Interest Ratio / Days to Cover
Last Record Date
November, 15 2021
Outstanding Shares
Float Size
Short Percent of Float
Today's Trading Volume
Average Trading Volume
Today's Volume Vs. Average
Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Altamira Therapeutics ?

Sign up to receive the latest short interest report for Altamira Therapeutics and its competitors with MarketBeat's FREE newsletter.

Altamira Therapeutics (NASDAQ:CYTO) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/15/202175,900 shares $182.16 thousand +19.5%1.1%0 $2.40
10/29/202163,500 shares $104.14 thousand +212.8%0.9%0.3 $1.64
10/15/202120,300 shares $37.96 thousand -51.9%0.3%0 $1.87
9/30/202142,200 shares $84.82 thousand -19.5%0.6%0.1 $2.01
9/15/202152,400 shares $118.95 thousand -26.9%0.8%0.1 $2.27
8/31/202171,700 shares $193.59 thousand -51.3%1.1%0.1 $2.70
8/13/2021147,200 shares $447.49 thousand No Change2.2%0.1 $3.04

Institutional Investors Shorting Altamira Therapeutics (NASDAQ:CYTO)

This table shows institutional investors, funds, and major shareholders that have reported short positions as of their most recent reporting period. Most commonly, these investors have purchased put options on shares of Altamira Therapeutics. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Reporting DateInvestor NameShares Shorted (Previous)Shares Shorted (Current)Position ChangePosition Size
11/9/2021Concourse Financial Group Securities Inc.N/A0N/A$0.00

Altamira Therapeutics (NASDAQ:CYTO) Short Interest Frequently Asked Questions

What is Altamira Therapeutics' current short interest?

Short interest is the volume of Altamira Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 75,900 shares of CYTO short. 1.13% of Altamira Therapeutics' shares are currently sold short. Learn More on Altamira Therapeutics' current short interest.

Which institutional investors are shorting Altamira Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Altamira Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Altamira Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.13% of Altamira Therapeutics' floating shares are currently sold short.

Is Altamira Therapeutics' short interest increasing or decreasing?

Altamira Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 75,900 shares, an increase of 19.5% from the previous total of 63,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Altamira Therapeutics' float size?

Altamira Therapeutics currently has issued a total of 11,417,000 shares. Some of Altamira Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Altamira Therapeutics currently has a public float of 6,730,000 shares.

How does Altamira Therapeutics' short interest compare to its competitors?

1.13% of Altamira Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Altamira Therapeutics: Assertio Holdings, Inc. (2.96%), IntelGenx Technologies Corp. (0.00%), Galecto, Inc. (0.59%), Odonate Therapeutics, Inc. (0.90%), Evofem Biosciences, Inc. (0.00%), Zosano Pharma Co. (6.05%), Agile Therapeutics, Inc. (0.00%), Ocuphire Pharma, Inc. (0.00%), Abeona Therapeutics Inc (2.41%), and Eledon Pharmaceuticals, Inc. (1.26%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Altamira Therapeutics stock?

Short selling CYTO is an investing strategy that aims to generate trading profit from Altamira Therapeutics as its price is falling. To short Altamira Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Altamira Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Altamira Therapeutics?

A short squeeze for Altamira Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTO, which in turn drives the price of the stock up even further.

How often is Altamira Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTO, twice per month. The most recent reporting period available is November, 15 2021.

This page was last updated on 12/8/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.